ZFP36
mRNA decay activator protein ZFP36
Also known as: G0S24, NUP475, RNF162A, TIS11, TTP, TTP_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P26651
- Gene
- ZFP36
- Ensembl
- ENSG00000128016
- Chromosome
- 19
- Canonical length
- 326 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Intermediate filaments
OverviewNCBI Gene
Enables several functions, including 14-3-3 protein binding activity; mRNA 3'-UTR AU-rich region binding activity; and protein-RNA sequence-specific adaptor activity. Involved in several processes, including cellular response to cytokine stimulus; cellular response to epidermal growth factor stimulus; and regulation of gene expression. Acts upstream of or within mRNA catabolic process. Located in cytoplasmic ribonucleoprotein granule; cytosol; and nucleus. Part of ribonucleoprotein complex. Biomarker of breast cancer. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
326 residues, UniProt reviewed canonical sequence.
>P26651|ZFP36
1 MDLTAIYESL LSLSPDVPVP SDHGGTESSP GWGSSGPWSL SPSDSSPSGV TSRLPGRSTS
61 LVEGRSCGWV PPPPGFAPLA PRLGPELSPS PTSPTATSTT PSRYKTELCR TFSESGRCRY
121 GAKCQFAHGL GELRQANRHP KYKTELCHKF YLQGRCPYGS RCHFIHNPSE DLAAPGHPPV
181 LRQSISFSGL PSGRRTSPPP PGLAGPSLSS SSFSPSSSPP PPGDLPLSPS AFSAAPGTPL
241 ARRDPTPVCC PSCRRATPIS VWGPLGGLVR TPSVQSLGSD PDEYASSGSS LGGSDSPVFE
301 AGVFAPPQPV AAPRRLPIFN RISVSELocalizationUniProt · AlphaFold · HPA
Whether an antibody against ZFP36 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.66
- Highest tissue expression
- 1,477 nTPM
Expression across tissuesHPA
Tissue
- adipose tissue: 1,477 nTPM
- lung: 1,096 nTPM
- fallopian tube: 942 nTPM
- skin: 810 nTPM
- breast: 719 nTPM
- bone marrow: 704 nTPM
Single-cell type
- decidual stromal cells: 4,942 nCPM
- esophageal apical cells: 4,461 nCPM
- epididymal basal cells: 3,050 nCPM
- ovarian stromal cells: 2,957 nCPM
- neutrophils: 2,521 nCPM
- smooth muscle cells: 2,012 nCPM
Immune cell
- neutrophil: 315 nTPM
- basophil: 123 nTPM
- non-classical monocyte: 96 nTPM
- classical monocyte: 72 nTPM
- intermediate monocyte: 70 nTPM
- myeloid DC: 69 nTPM
Brain region
- medulla oblongata: 243 nTPM
- thalamus: 151 nTPM
- hypothalamus: 148 nTPM
- spinal cord: 137 nTPM
- white matter: 135 nTPM
- choroid plexus: 118 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.53
- gnomAD pLI
- 0.75
- gnomAD missense Z
- 0.79
- DepMap mean gene effect
- -0.08
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- 3'-UTR-mediated mRNA destabilization
- 3'-UTR-mediated mRNA stabilization
- cellular response to epidermal growth factor stimulus
- cellular response to fibroblast growth factor stimulus
- cellular response to glucocorticoid stimulus
- cellular response to granulocyte macrophage colony-stimulating factor stimulus
- cellular response to lipopolysaccharide
- cellular response to tumor necrosis factor
- MAPK cascade
- miRNA-mediated gene silencing by inhibition of translation
- mRNA catabolic process
- mRNA transport
- negative regulation of 3'-UTR-mediated mRNA stabilization
- negative regulation of cytokine production involved in inflammatory response
- negative regulation of erythrocyte differentiation
- negative regulation of interleukin-2 production
- negative regulation of transcription by RNA polymerase II
- negative regulation of viral transcription
- nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay
- nuclear-transcribed mRNA catabolic process, deadenylation-independent decay
- nuclear-transcribed mRNA poly(A) tail shortening
- p38MAPK cascade
- positive regulation of fat cell differentiation
- positive regulation of intracellular mRNA localization
- positive regulation of miRNA-mediated gene silencing
- positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay
- positive regulation of nuclear-transcribed mRNA poly(A) tail shortening
- regulation of keratinocyte apoptotic process
- regulation of keratinocyte differentiation
- regulation of keratinocyte proliferation
- regulation of mRNA stability
- regulation of tumor necrosis factor production
- response to starvation
- response to wounding
- negative regulation of polynucleotide adenylyltransferase activity
- positive regulation of deadenylation-independent decapping of nuclear-transcribed mRNA
Molecular functions
- 14-3-3 protein binding
- C-C chemokine binding
- DNA binding
- enzyme binding
- heat shock protein binding
- mRNA 3'-UTR AU-rich region binding
- mRNA binding
- protein kinase binding
- protein-containing complex binding
- protein-RNA sequence-specific adaptor activity
- RNA binding
- RNA polymerase binding
- zinc ion binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of ZFP36 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ZFP36 as an antibody target. Whether an autoantibody or antibody against ZFP36 could matter depends on whether native ZFP36 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ZFP36 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label ZFP36 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...